VIA
IBRX icon

Virtus Investment Advisers’s ImmunityBio IBRX Stock Holding History

Virtus Investment Advisers’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.43M Sell
163,786
-193,961
-54% -$1.47M 0.33% 129
2026
Q1 		$2.74M Buy
357,747
+68,166
+24% +$467K 0.76% 4
2025
Q4 		$573K Buy
289,581
+150,272
+108% +$340K 0.16% 226
2025
Q3 		$343K Hold
139,309
– – 0.1% 236
2025
Q2 		$368K Buy
139,309
+21,209
+18% +$57K 0.12% 233
2025
Q1 		$355K Buy
+118,100
New +$358K 0.1% 225

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Virtus Investment Advisers's IBRX Position: Q2 2026 in Review

Virtus Investment Advisers reduced its ImmunityBio (IBRX) stake by 54% in Q2 2026, selling an estimated $1.47M and leaving 163,786 shares worth $1.43M. The position accounts for 0.33% of the portfolio, ranked #129.

Virtus Investment Advisers first reported a position in IBRX in Q1 2025 and has held it in 6 quarters since. The position peaked at $2.74M in Q1 2026. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Virtus Investment Advisers held 163,786 shares of ImmunityBio worth $1.43M as of Q2 2026.
  • Virtus Investment Advisers sold 193,961 ImmunityBio shares in Q2 2026, an estimated $1.47M.
  • ImmunityBio made up 0.33% of Virtus Investment Advisers's portfolio in Q2 2026, its #129 holding.
  • Virtus Investment Advisers first reported a position in ImmunityBio in Q1 2025 and has held it in 6 quarters since.
  • Virtus Investment Advisers's ImmunityBio position peaked at $2.74M in Q1 2026.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.